Table 4 Review of current literature investigating tumor budding in a rectum cancer patient who was treated with neoadjuvant chemoradiotherapy
From: Tumor budding for predicting prognosis of resected rectum cancer after neoadjuvant treatment
Due et al. [26]. | Jager et al. [25]. | Our study | ||
|---|---|---|---|---|
Design | Retrospective | Retrospective | Retrospective | |
Follow-up period | 2001–2005 | 2003–2012 | 2013–2018 | |
Patients (n) | 96 | 128 | 75 | |
Neoadjuvant protocols | Radiotherapy | 3000 cGy in 10 fractions in 2 weeks | 45–50 Gy 5–6 weeks | 45 Gy 4 weeks |
Concurrent chemotherapy | Absent | 5-Flouracil, capecitabine, oxaliplatin | 5- Flouracil, capecitabine, | |
Interval to surgery (weeks) | 2–3 | 3–9 | 8–12 | |
Postoperative treatment (n) | All patients | 58 patients | All patients | |
Median follow-up (months) | 70.8 | 84 | 35 | |
Tumor budding | 0–9 buds: low grade 10 or more buds: high grade | 0 buds: none 1 bud: mild 2–4 buds: moderate 5 or more buds: severe | 0–4 buds: low budding 5–9 buds: intermediate budding 10 or more buds: high budding | |
Association with | Disease-free survival | Relapse-free survival, distant and overall recurrence | Disease-free survival | |
Result | Low vs high | None-mild vs moderate-severe | Low-intermediate vs high | |
5-year DFS, 87.5% vs 55.6% | 5-year RFS, 90% vs %71% | 3-year DFS, 61% vs 24% | ||